Skip to main content
CPRX logo

Catalyst Pharmaceuticals, Inc.

CPRXNASDAQHealthcareBiotechnology

$31.49Today:- (-)1Y +53.24%

As of Jul 21, 2026 close

Market cap
$4.00B
P/E (TTM)
18.06
Forward P/E
16.14
Dividend yield
-
52-week range
$20.26$32.56
Volume (live)
-
Avg. volume (3M)
-

Catalyst Pharmaceuticals (CPRX) Key Statistics & Financial Metrics

Complete stock analysis with 60+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.

Stock Valuation Metrics

Market value, earnings multiples, and pricing ratios

Stock Price

Current price, 52-week range, and moving averages

Current Price$31.49
1-Day Change0.00%
52-Week High$32.56
52-Week Low$20.26
YTD Change+36.03%
1-Year Change+53.24%
50-Day MA$31.35
200-Day MA$25.64

Profitability & Financial Performance

Profit margins, return metrics, and earnings analysis

Growth Rates (YoY)

Year-over-year growth metrics

Revenue Growth+11.65%

Financial Health & Dividends

Balance sheet analysis, debt ratios, and dividend metrics

Fair Value & Intrinsic Value

Lynch fair value, Graham number, and valuation models

Lynch Upside/Downside−33.05%
Graham Upside/Downside−43.88%

Source: Market prices and company fundamentals from financial filings. Data as of Jul 21, 2026. Data sources and methodology

Frequently Asked Questions About Catalyst Pharmaceuticals Statistics

What are the key financial metrics for CPRX?

Catalyst Pharmaceuticals, Inc. (CPRX) statistics include 60+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.

What is CPRX's valuation analysis?

The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Catalyst Pharmaceuticals is overvalued or undervalued.

How do I read CPRX's profitability ratios?

Catalyst Pharmaceuticals's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.

What do CPRX's debt ratios indicate?

The financial health section shows Catalyst Pharmaceuticals's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.

What is CPRX's dividend analysis?

The dividend section covers Catalyst Pharmaceuticals's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.